

Giulia Romano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11398175/publications.pdf>

Version: 2024-02-01

33
papers

3,738
citations

257450

24
h-index

330143

37
g-index

37
all docs

37
docs citations

37
times ranked

6303
citing authors

#	ARTICLE	IF	CITATIONS
1	Disparities in Lung Cancer: miRNA Isoform Characterization in Lung Adenocarcinoma. <i>Cancers</i> , 2022, 14, 773.	3.7	4
2	microRNAs as Novel Therapeutics in Cancer. <i>Cancers</i> , 2021, 13, 1526.	3.7	25
3	Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer. <i>Cancers</i> , 2021, 13, 1372.	3.7	28
4	MiREDiBase, a manually curated database of validated and putative editing events in microRNAs. <i>Scientific Data</i> , 2021, 8, 199.	5.3	18
5	Extracellular Vesicles in Lung Cancer Metastasis and Their Clinical Applications. <i>Cancers</i> , 2021, 13, 5633.	3.7	14
6	Non-Coding RNA Editing in Cancer Pathogenesis. <i>Cancers</i> , 2020, 12, 1845.	3.7	16
7	MiR-124a Regulates Extracellular Vesicle Release by Targeting GTPase Rabs in Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1454.	2.8	8
8	isoTar: Consensus Target Prediction with Enrichment Analysis for MicroRNAs Harboring Editing Sites and Other Variations. <i>Methods in Molecular Biology</i> , 2019, 1970, 211-235.	0.9	13
9	ncRNA Editing: Functional Characterization and Computational Resources. <i>Methods in Molecular Biology</i> , 2019, 1912, 133-174.	0.9	20
10	Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. <i>Cell Death and Differentiation</i> , 2019, 26, 1267-1282.	11.2	47
11	Tissue and exosomal miRNA editing in Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 10222.	3.3	38
12	RNA Methylation in ncRNA: Classes, Detection, and Molecular Associations. <i>Frontiers in Genetics</i> , 2018, 9, 243.	2.3	40
13	RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. <i>Molecular Therapy</i> , 2017, 25, 1544-1555.	8.2	115
14	Selective targeting of point-mutated KRAS through artificial microRNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4203-E4212.	7.1	38
15	Small non-coding RNA and cancer. <i>Carcinogenesis</i> , 2017, 38, 485-491.	2.8	352
16	MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b. <i>Oncotarget</i> , 2016, 7, 580-592.	1.8	84
17	miR-579-3p controls melanoma progression and resistance to target therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5005-13.	7.1	99
18	microRNA editing in seed region aligns with cellular changes in hypoxic conditions. <i>Nucleic Acids Research</i> , 2016, 44, 6298-6308.	14.5	41

#	ARTICLE	IF	CITATIONS
19	miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of <i>NRAS</i> . <i>Oncotarget</i> , 2016, 7, 19531-19547.	1.8	36
20	A set of NF- κ B-regulated microRNAs induces acquired TRAIL resistance in Lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3355-64.	7.1	68
21	MicroRNA and cancer – A brief overview. <i>Advances in Biological Regulation</i> , 2015, 57, 1-9.	2.3	544
22	miR-15b/16-2 Regulates Factors That Promote p53 Phosphorylation and Augments the DNA Damage Response following Radiation in the Lung. <i>Journal of Biological Chemistry</i> , 2014, 289, 26406-26416.	3.4	55
23	miR-Synth: a computational resource for the design of multi-site multi-target synthetic miRNAs. <i>Nucleic Acids Research</i> , 2014, 42, 5416-5425.	14.5	36
24	Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene. <i>Blood</i> , 2014, 124, 259-262.	1.4	11
25	Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8573-8578.	7.1	105
26	MiR-34a/c-Dependent PDGFR- β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67581.	2.5	103
27	miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells. <i>PLoS ONE</i> , 2013, 8, e74466.	2.5	84
28	MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16570-16575.	7.1	150
29	miR-212 Increases Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Sensitivity in Non-Small Cell Lung Cancer by Targeting the Antiapoptotic Protein PED. <i>Cancer Research</i> , 2010, 70, 3638-3646.	0.9	143
30	PED is overexpressed and mediates TRAIL resistance in human non-small cell lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2416-2426.	3.6	36
31	Contrast agents and renal cell apoptosis. <i>European Heart Journal</i> , 2008, 29, 2569-2576.	2.2	187
32	Akt Regulates Drug-Induced Cell Death through Bcl-w Downregulation. <i>PLoS ONE</i> , 2008, 3, e4070.	2.5	20
33	Selective inhibition of PED protein expression sensitizes B-cell chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis. <i>International Journal of Cancer</i> , 2007, 120, 1215-1222.	5.1	34